Prophylactic intraocular pressure lowering measures in anti-vascular endothelial growth factor therapy: A systematic review and meta-analysis
The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections (IVIs) has revolutionized the treatment of patients with retinal vascular disorders such as neovascular age-related macular degeneration (nvAMD) and diabetic macular edema (DME). The average nvAMD or DME patient receives a total of 6 to 11.5 IVIs per year based on real-world data.9
Source: Survey of Ophthalmology - Category: Opthalmology Authors: Parnian Arjmand, Caberry W. Yu, Marko M. Popovic, Aaditeya Jhaveri, Efrem D. Mandelcorn Tags: Review article Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Diabetes | Endocrinology | Opthalmology | Vitamin A